A Study of CD8+ T Cell Imaging During Treatment in People With Non-Small Cell Lung Cancer
The purpose of this study to learn whether PET/CT (positron emission tomography/computed tomography) scans using an imaging agent (radiotracer) called zirconium Zr 89 crefmirlimab berdoxam is a safe and effective way to identify CD8+ T cells
Checked against the public recordLast updated Aug 26, 2026 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Diagnostic
- Study type
- Interventional
- Phase
- Phase 1
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Interventions being studied
- Drug: Zirconium Zr 89 crefmirlimab berdoxam; Diagnostic Test: PET/CT Scan
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Patient must be 18 years of age or older at the time of signing the informed consent. * Patient has a histologically confirmed diagnosis of metastatic non-small cell lung cancer * Patient is enrolled in the engineered TIL cell therapy protocol OBX115-23-01, but has not received the treatment yet. * Men and women of child-producing potential, use of effective double barrier contraceptive methods during the study, up to 30 days after the last administration of the investigational product. * Patient or legally authorized representative provided signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. * Patient or legally authorized representative provided written authorization for use and disclosure of protected health information. Exclusion Criteria: * Pregnant or breastfeeding women * Patients with a history of splenectomy or significant splenic dysfunction (e.g., as evidenced by splenomegaly or a history of recurrent infections due to impaired immune function)
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Memorial Sloan Kettering at Basking Ridge (Consent Only)Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (Consent Only)Middletown, New Jersey
- Memorial Sloan Kettering Bergen (Consent Only)Montvale, New Jersey
- Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Consent only)Commack, New York
- Memorial Sloan Kettering Westchester (Consent only)Harrison, New York
- Memorial Sloan Kettering Cancer Center (All protocol activities)New York, New York
- Memorial Sloan Kettering Cancer Center @ Nassau (Consent only)Uniondale, New York
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Aug 26, 2026. Always confirm current availability with the study team.